Logo 1 Logo 2

Clinical Trial Details

Trial ID: L2196
Source ID: NCT00456027
Associated Drug: Rhgad65 Formulated In Alhydrogel® (Diamyd®)
Title: Safety of Diamyd® in Patients With LADA (Latent Autoimmune Diabetes in Adult)
Acronym:
Status: COMPLETED
Study Results: NO
Results:
Conditions: Latent Autoimmune Diabetes in Adult (LADA)
Interventions: DRUG: rhGAD65 formulated in Alhydrogel® (Diamyd®)
Outcome Measures: Primary: The development over time of safety variables, i.e. injection site discomfort, vital signs, laboratory values and AEs/SAEs as well as development of diabetes status, i.e. HbA1c, C-peptide, blood glucose and insulin requirement., 30 months |
Sponsor/Collaborators: Sponsor: Diamyd Therapeutics AB
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases: PHASE2
Enrollment: 160
Study Type: INTERVENTIONAL
Study Designs: Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
Start Date: 2004-12
Completion Date: 2008-04
Results First Posted:
Last Update Posted: 2011-06-10
Locations: Alingsås Hospital, Alingsås, Sweden|Falu Hospital, Falun, Sweden|Capio Lundby Hospital, Göteborg, Sweden|Helsingborg Hospital, Helsingborg, Sweden|Härnösand Hospital, Härnösand, Sweden|Karlstad Central Hospital, Karlstad, Sweden|Central Hospital, Kristianstad, Kristianstad, Sweden|Sunderby Hospital, Luleå, Sweden|University Hospital MAS, Malmö, Sweden|Vrinnevi Hospital, Norrköping, Sweden|Skellefteå Hospital, Skellefteå, Sweden|S:t Göran Hospital, Stockholm, Sweden|Stockholm South General Hospital, Stockholm, Sweden|Norrlands University Hospital, Umeå, Sweden|Uppsala University Hospital, Uppsala, Sweden|Växjö Central Hospital, Växjö, Sweden|Odensala Health Clinic, Östersund, Sweden
URL: https://clinicaltrials.gov/show/NCT00456027

Drug ID Drug Name Type DrugBank ID Targets Category Latest Progress